This is unpublished

George E.
Georges
M.D.

George E. Georges

(206) 667-6886

Fred Hutchinson Cancer Center 

1100 Fairview Ave. N, D1-100 

Seattle, WA 98109     

he, him, his
Physician & Research Faculty
Pinned
Academic
Associate Professor, Clinical Research Division, Fred Hutchinson Cancer Center
Associate Professor, Division of Medical Oncology, University of Washington
Sites of Practice
Fred Hutchinson Cancer Center - South Lake Union
Fred Hutchinson Cancer Center at UW Medical Center – Montlake

Photo: Fred Hutch

Education, Training, Board Certifications 

  • M.D., University of California, San Francisco 
  • Residency, University of Texas, Southwestern
  • Fellowship, UW 
  • Medical Oncology, American Board of Internal Medicine 
  • Internal Medicine, American Board of Internal Medicine

Clinical Expertise 

  • Hematopoietic stem cell transplant 
  • Hematologic malignancies 
  • Graft-vs.-host disease 
  • Autoimmune diseases

Affiliations 

 

Publications

PubMed

 

Research and/or clinical interests 

Dr. George Georges is a medical oncologist who treats patients with blood disorders such as leukemia, lymphoma, multiple myeloma, and myelodysplastic syndrome. Through his research he seeks ways to reduce the toxicity of blood stem cell transplantation. Dr. Georges’ research interests lie in the following areas: 

  • Hematopoietic cell transplantation for severe autoimmune diseases: clinical trials evaluating autologous or allogeneic transplantation for diseases including systemic sclerosis, multiple sclerosis, aplastic anemia, and other neurologic autoimmune diseases such as chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, Stiff Person Syndrome. 
  • Nonmyeloablative hematopoietic cell transplantation: regimens to reduce the toxicity of allogeneic transplantation, particularly in older patients or patients with medical comorbidities. 
  • Hematopoietic stem cell and T cell gene therapy: laboratory-based studies on hematopoietic stem cell expansion and genetic correction of underlying disease.
  • Quality of life and late effects after hematopoietic cell transplantation.